HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.

Abstract
A successful therapy is presented using the antiplatelet agent abciximab, alone, in an ST-segment elevation acute myocardial infarction. The patient was treated in a center with permanent catheterization facilities. Clinical trials are necessary to validate the efficacy and the cost-effectiveness of this clinical decision and therapeutic option.
AuthorsA Mesquita, J Baptista, J Palos, R Seabra-Gomes
JournalThe Journal of invasive cardiology (J Invasive Cardiol) Vol. 11 Issue 6 Pg. 379-82 (Jun 1999) ISSN: 1042-3931 [Print] United States
PMID10745556 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Abciximab
Topics
  • Abciximab
  • Adult
  • Antibodies, Monoclonal (therapeutic use)
  • Coronary Angiography
  • Electrocardiography
  • Female
  • Humans
  • Immunoglobulin Fab Fragments (therapeutic use)
  • Myocardial Infarction (diagnosis, drug therapy, physiopathology)
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: